Major 30-day complications after radical radiotherapy A population-based analysis and comparison with surgery

Cancer

Volumn 115, Issue 2, 2009, Pages 293-302

  Alibhai, Shabbir M H ^a,b,c,d   Leach, Marc ^a   Warde, Padraig ^c,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Comorbidity; Major complications; Mortality; Radical prostatectomy; Radiotherapy; Short term complications

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; CANADA; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; HOSPITAL MANAGEMENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RESPIRATORY TRACT DISEASE; UROGENITAL TRACT DISEASE;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 59449094663     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24008     Document Type: Article

References (41)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Lu-Yao GL, Yao S-L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906-910.
3. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer. 2001;91:2302-2314.
4. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol. 2007;177:932-936.
5. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer. 2006;107:2392-2400.
6. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88:1122-1130.
7. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92:1582-1592.
8. Fleshner N, Rakovitch E, Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol. 2000;163:1461-1466.
9. Alibhai SMH, Krahn MD, Cohen MM, Fleshner NE, TomlinsonG,NaglieG. Isthereagebiasinthetreatment of localized prostate carcinoma? Cancer. 2004;100: 72-81.
10. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29-33.
11. Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol. 2005;23:2201-2207.
12. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112-3124.
13. Alibhai SM, Leach M, Tomlinson G, et al. Thirty-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005;97:1525-1532.
14. Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. Can J Urol. 2004;11: 2110-2117.
15. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053.
16. Holowaty EJ, Moravan V, Lee G, Chong N, Dale D. A Reabstraction Study to Estimate the Completeness and Accuracy of Data Elements in the Ontario Cancer Registry. A Report to Health Canada. Ottawa, Ontario: Public Health Agency of Canada; 1996.
17. Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988; 41:495-501.
18. Alibhai SMH. Do Age and Comorbidity Influence the Treatment of Localized Prostate Cancer? Toronto Department of Health Administration. Toronto, Canada: University of Toronto; 2001.
19. Ontario Hospital Association, Ontario Ministry of Health, Hospital Medical Records Institute. Report of the Ontario Data Quality Reabstracting Study. Toronto, Canada: Ontario Hospital Association; 1991.
20. Tu JV, Austin P, Naylor CD, Iron K, Zhang H. Acute myocardial infarction outcomes in Ontario: methods appendix. In: Naylor CD, Slaughter PM, eds. Cardiovascular Health and Services in Ontario: an ICES Atlas. Toronto, Canada: Institute for Clinical Evaluative Sciences; 1999:25-30.
21. Lu-Yao GL, Albertsen P, Warren J, Yao S-L. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy-a population-based study. Urology. 1999;54:301-307.
22. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346: 1138-1144.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChron Dis. 1987; 40:373-383.
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
25. Rochon PA, Katz JN, Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. Med Care. 1996;34:1093-1101.
26. Harrell FE Jr. Multivariable modeling strategies. In: Harrell FE Jr, ed. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2001:53-86.
27. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
28. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health. 1991;81:1630-1635.
29. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43:316-381.
30. Roach M 3rd. Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am. 2004;31:353-366.
31. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993; 2:487-493.
32. Shipley WU, Zietman AL, Hanks GE, et al. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol. 1994;152(5 pt 2):1799-1805.
33. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21: 3972-3978.
34. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61: 1019-1034.
35. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol. 2007;83:31-41.
36. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in 3 Surveillance, Epidemiology, and End Results areas. J Clin Oncol. 1996; 14:2258-2265.
37. Lilleby W, Fossa SD, Woehre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys. 1999;43:735-743.
38. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998; 16:275-283.
39. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology. 2000;55:91-96.
40. Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003;21:3318-3327.
41. Talcott JA, Clark JA, Manola J, Mitchell SP. Bringing prostate cancer quality of life research back to the bedside: translating numbers into a format that patients can understand. J Urol. 2006;176(4 pt 1):1558-1563; discussion 1563-1564.